Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2b Multi-center Clinical Trials to Clarify the Efficacy and Adaptation Target of DA9601 in Patients With Acute and Chronic Gastritis, and to Determine the Optimal Clinical Dosage and Administration.

NCT07139886 is registered in ClinicalTrials.gov with Dong-A ST Co., Ltd. as lead sponsor.

NCT NCT07139886
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07139886 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2b Multi-center Clinical Trials to Clarify the Efficacy and Adaptation Target of DA9601 in Patients With Acute and Chronic Gastritis, and to Determine the Optimal Clinical Dosage and Administration.
Lead sponsor
Dong-A ST Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
March 14, 1997
Completion date
July 8, 1999
Enrollment
212 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute gastritis, chronic gastritis